Mindstrong Health Announces $15M Series B
Mindstrong , a healthcare company dedicated to transforming brain health through measurement science, announced that it has secured a $15M Series B round of financing from a syndicate of leading investors and healthcare innovators.
“We appreciate the continued support of our early investors and we welcome Bezos Expeditions and Decheng Capital in our journey to transform brain healthcare. As the first company to develop comprehensive care pathways based on our passively-collected, continuous and objective measures of cognitive function and mood, we are committed to improving behavioral healthcare with delivery models that move care from episodic clinic visits to preemptive outreach care that is technology enabled.” – Founder and CEO, Paul Dagum.
The company announced a $14M Series A in June of 2017. It will use the proceeds to scale the business and advance commercial deployments with its partners across healthcare verticals, building upon progress made since the Series A.
This year, the company announced a partnership with Takeda Pharmaceutical Company Limited to apply Mindstrong’s technology to identify digital biomarkers in schizophrenia and treatment-resistant depression. Mindstrong is also partnered with Blackthorn Therapeutics. Furthermore, the company published a study in NPJ Digital Medicine showing that Mindstrong technology predicted individuals’ performance on gold-standard neurocognitive tests used by clinicians to measure and manage brain health and disorders. It continues to advance clinical and translational research across brain health conditions on a global scale.
